Average Risks of Breast and Ovarian Cancer Associated with BRCA1 or BRCA2 Mutations Detected in Case Series Unselected for Family History: A Combined Analysis of 22 Studies

Cited by (1,009)

Items 201–300 of 1,009

1. Diagnosis and Treatment of Breast Cancer in Young Women
   Lorenzo Rossi, Calogero Mazzara, Olivia Pagani · 2019 · Current Treatment Options in Oncology
2. Whole blood-derived miRNA profiles as potential new tools for ovarian cancer screening
   Sebastian F. Häusler, Andreas Keller, P. Anoop Chandran, K Ziegler, K Zipp, Stefan Heuer, Mathias Krockenberger, Jörg Bernhard Engel, Arnd Hönig, Matthias Scheffler et al. · 2010 · British Journal of Cancer
3. Cancer Risk Elicitation and Communication: Lessons from the Psychology of Risk Perception
   William M. P. Klein, Michael Edward Stefanek · 2007 · CA A Cancer Journal for Clinicians
4. Common Breast Cancer Susceptibility Alleles and the Risk of Breast Cancer for BRCA1 and BRCA2 Mutation Carriers: Implications for Risk Prediction
   Antonis C. Antoniou, Jonathan Beesley, Lesley McGuffog, Olga M. Sinilnikova, Sue C. Healey, Susan L. Neuhausen, Yuan Chun Ding, Timothy Richard Rebbeck, Jeffrey N. Weitzel, Henry T. Lynch et al. · 2010 · Cancer Research
5. Effect of pregnancy as a risk factor for breast cancer in BRCA1/BRCA2 mutation carriers
   Carey A. Cullinane, Jan Lubiński, Susan L. Neuhausen, Parviz Ghadirian, Henry T. Lynch, Claudine J. Isaacs, Barbara Weber, Pål Møller, Kenneth Offit, Charmaine Kim‐Sing et al. · 2005 · International Journal of Cancer
6. BRCA1, BRCA2 and TP53 mutations in very early-onset breast cancer with associated risks to relatives
   Fiona I. Lalloo, J M Varley, Anthony Moran, David Ellis, Lindsay O’Dair, Paul D.P. Pharoah, Antonis C. Antoniou, Roger Hartley, Andrew Shenton, Sheila Seal et al. · 2006 · European Journal of Cancer
7. Risk of Colorectal Cancer in Monoallelic and Biallelic Carriers of MYH Mutations: A Population-Based Case-Family Study
   Mark A. Jenkins, Marina E. Croitoru, Neerav Monga, Sean Patrick Cleary, Michelle Cotterchio, John Llewelyn Hopper, Steve Gallinger · 2006 · Cancer Epidemiology Biomarkers & Prevention
8. Genetic Factors, Adherence to Healthy Lifestyle Behavior, and Risk of Invasive Breast Cancer Among Women in the UK Biobank
   Rhonda Arthur, Tao Wang, Xiaonan Xue, Victor Kamensky, Thomas E. Rohan · 2019 · JNCI Journal of the National Cancer Institute
9. Anticancer Activity of Sulforaphane: The Epigenetic Mechanisms and the Nrf2 Signaling Pathway
   Xuling Su, Xin Mei Jiang, Lingbin Meng, Xiaoming Dong, Yanjun Shen, Ying Xin · 2018 · Oxidative Medicine and Cellular Longevity
10. Tamoxifen and Risk of Contralateral Breast Cancer for <i>BRCA1</i> and <i>BRCA2</i> Mutation Carriers
    Phillips, Kelly-Anne, Milne, Roger L., Rookus, Matti A., Daly, Mary B., Antoniou, Antonis C., Peock, Susan, Frost, Debra, Easton, Douglas F., Ellis, Steve, Friedlander, Michael L. et al. · 2013 · Journal of Clinical Oncology
11. Role of BRCA Mutations in the Modulation of Response to Platinum Therapy
    Sanghamitra Mylavarapu, Asmita Das, Monideepa Roy · 2018 · Frontiers in Oncology
12. Elevated Risk of Prostate Cancer Among Men With Lynch Syndrome
    Victoria M. Raymond, Bhramar Mukherjee, Fei Wang, Shu-Chen Huang, Elena M. Stoffel, Fay Kastrinos, Sapna Syngal, Kathleen A. Cooney, Stephen B. Gruber · 2013 · Journal of Clinical Oncology
13. Prevention and Management of Hereditary Breast Cancer
    Steven Alexander Narod, Kenneth Offit · 2005 · Journal of Clinical Oncology
14. Hereditary breast cancer; Genetic penetrance and current status with BRCA
    Morteza Mahdavi, Mohammadreza Nassiri, Mohammad Mahdi Kooshyar, Masoume Vakili Azghandi, Amir Avan, Ryan Sandry, Suja Pillai, Alfred King-yin Lam, Vinod Gopalan · 2018 · Journal of Cellular Physiology
15. The complex genetic landscape of familial breast cancer
    Lorenzo Melchor, Javier J. Benitez · 2013 · Human Genetics
16. An international initiative to identify genetic modifiers of cancer risk in BRCA1 and BRCA2 mutation carriers: the Consortium of Investigators of Modifiers of BRCA1 and BRCA2 (CIMBA)
    CIMBA, Georgia Chenevix‐Trench, Roger Laughlin Milne, Antonis C. Antoniou, Fergus J. Couch, Douglas F. Easton, David E. Goldgar · 2007 · Breast Cancer Research
17. Common Genetic Variants and Modification of Penetrance of BRCA2-Associated Breast Cancer
    Mia M. Gaudet, Tomas Kirchhoff, Todd J. Green, Joseph Vijai, Joshua M. Korn, Candace Guiducci, Ayellet V. Segrè, Kate McGee, Lesley McGuffog, Christiana Kartsonaki et al. · 2010 · PLoS Genetics
18. European experts consensus: BRCA/homologous recombination deficiency testing in first-line ovarian cancer
    Ignace B. Vergote, Antonio González-Martı́n, I. Ray-Coquard, Philipp Harter, Nicoletta Colombo, Pascal Pujol, Domenica Lorusso, Mansoor Raza Mirza, Birutė Brasiūnienė, R. Madry et al. · 2021 · Annals of Oncology
19. Hormone Replacement Therapy and Life Expectancy After Prophylactic Oophorectomy in Women With BRCA1/2 Mutations: A Decision Analysis
    Katrina Armstrong, J. Sanford Schwartz, Thomas Christopher Randall, Stephen C. Rubin, Barbara Weber · 2004 · Journal of Clinical Oncology
20. Prophylactic Salpingectomy and Delayed Oophorectomy as an Alternative for BRCA Mutation Carriers
    Janice S. Kwon, Anna V. Tinker, Gary K. Pansegrau, Jessica Nell McAlpine, Melissa Housty, Mary McCullum, C. Blake Gilks · 2013 · Obstetrics and Gynecology
21. BRCA mutations in the management of breast cancer: the state of the art
    Steven Alexander Narod · 2010 · Nature Reviews Clinical Oncology
22. BRCA2 suppresses replication stress-induced mitotic and G1 abnormalities through homologous recombination
    Weiran Feng, Maria Jasin · 2017 · Nature Communications
23. PARP Inhibitors in Ovarian Cancer
    Mittica, Gloria, Ghisoni, Eleonora, Giannone, Gaia, Genta, Sofia, Aglietta, Massimo, Sapino, Anna, Valabrega, Giorgio · 2018 · Recent Patents on Anti-Cancer Drug Discovery
24. Body mass index and risk of ovarian cancer
    Michael Fred Leitzmann, Corinna Koebnick, Kim N. Danforth, Louise Annette Brinton, Steven C. Moore, Albert R. Hollenbeck, Arthur G. Schatzkin, James Vincent Lacey · 2009 · Cancer
25. Hereditary ovarian cancer: Beyond the usual suspects
    Kathryn P. Pennington, Elizabeth M. Swisher · 2012 · Gynecologic Oncology
26. No efficacy of annual gynaecological screening in BRCA1/2 mutation carriers; an observational follow-up study
    Brenda B.J. Hermsen, Roelien I. Olivier, René H.M. Verheijen, Marc van Beurden, Joanne A. de Hullu, Leon F.A.G. Massuger, Curt W. Burger, Cecile T.M. Brekelmans, Marian J.E. Mourits, Geertruida H. de Bock et al. · 2007 · British Journal of Cancer
27. High Frequency of TP53 Mutation in BRCA1 and Sporadic Basal-like Carcinomas but not in BRCA1 Luminal Breast Tumors
    Élodie Manié, Anne Vincent‐Salomon, Jacqueline Lehmann‐Che, Gaëlle Pierron, Elisabeth Turpin, Mathilde Warcoin, Nadège Gruel, Ingrid Lebigot, Xavier Sastre‐Garau, Rosette Lidereau et al. · 2009 · Cancer Research
28. Identification and Management of Women With BRCA Mutations or Hereditary Predisposition for Breast and Ovarian Cancer
    Sandhya Pruthi, Bobbie S. Gostout, Noralane M. Lindor · 2010 · Mayo Clinic Proceedings
29. Oral contraceptive use and ovarian cancer risk among carriers of BRCA1 or BRCA2 mutations
    Alice S. Whittemore, Raymond R. Balise, Paul D.P. Pharoah, Richard A. DiCioccio, Ingrid A. Oakley-Girvan, Susan J. Ramus, Mary Beryl Daly, M B Usinowicz, Kim Garlinghouse-Jones, Bruce A.J. Ponder et al. · 2004 · British Journal of Cancer
30. Prevalence and Type ofBRCAMutations in Hispanics Undergoing Genetic Cancer Risk Assessment in the Southwestern United States: A Report From the Clinical Cancer Genetics Community Research Network
    Jeffrey N. Weitzel, Jessica Clague, Arelis Esther Martir-Negron, Raquel Ogaz, Josef Herzog, Charite Nicolette Ricker, Chelsy R. Jungbluth, C. Cina, Paul R. Duncan, Gary Walter Unzeitig et al. · 2012 · Journal of Clinical Oncology
31. Targeted sequencing of BRCA1 and BRCA2 across a large unselected breast cancer cohort suggests that one-third of mutations are somatic
    Christof Winter, Martin Nilsson, Eric Olsson, Anthony M. George, Y. Chen, Anders Kvist, Therese Törngren, Johan Vallon‐Christersson, Cecilia Hegardt, Jari Häkkinen et al. · 2016 · Annals of Oncology
32. Prediction of BRCA1-association in hereditary non-BRCA1/2 breast carcinomas with array-CGH
    Simon Andreas Joosse, Erik H. van Beers, Ivon H. G. Tielen, Hugo M. Horlings, Johannes L. Peterse, Nicoline Hoogerbrugge, Marjolijn J. L. Ligtenberg, Lodewyk F.A. Wessels, Priscilla Axwijk, Senno Verhoef et al. · 2008 · Breast Cancer Research and Treatment
33. Oral Contraceptives and Breast Cancer Risk in the International BRCA1/2 Carrier Cohort Study: A Report From EMBRACE, GENEPSO, GEO-HEBON, and the IBCCS Collaborating Group
    Richard M. Brohet, David E. Goldgar, Douglas F. Easton, Antonis C. Antoniou, Nadine Andrieu, Jenny C. Chang-Claude, Susan Peock, Rosalind A. Eeles, Margaret Cook, Carol Chu et al. · 2007 · Journal of Clinical Oncology
34. Population-based family studies in genetic epidemiology
    John Llewelyn Hopper, David Timothy Bishop, Douglas F. Easton · 2005 · The Lancet
35. A weighted cohort approach for analysing factors modifying disease risks in carriers of high‐risk susceptibility genes
    Antonis C. Antoniou, David E. Goldgar, Nadine Andrieu, Jenny C. Chang-Claude, Richard M. Brohet, Matti A. Rookus, Douglas F. Easton · 2005 · Genetic Epidemiology
36. Mechanisms of tissue and cell-type specificity in heritable traits and diseases
    Idan Hekselman, Esti Yeger‐Lotem · 2020 · Nature Reviews Genetics
37. Genetic and Histopathologic Evaluation ofBRCA1andBRCA2DNA Sequence Variants of Unknown Clinical Significance
    Georgia Chenevix‐Trench, Sue C. Healey, Sunil R. Lakhani, Paul Waring, Margaret C. Cummings, Ross I. Brinkworth, Amie M. Deffenbaugh, Lynn Anne Burbidge, Dmitry Pruss, Thaddeus Judkins et al. · 2006 · Cancer Research
38. The Angelina effect: immediate reach, grasp, and impact of going public
    Dina L. G. Borzekowski, Yue Guan, Katherine Clegg Smith, Lori Hamby Erby, DEBRA L. ROTER · 2013 · Genetics in Medicine
39. Biallelic Deleterious BRCA1 Mutations in a Woman with Early-Onset Ovarian Cancer
    Susan M. Domchek, Jiang-bo Tang, Jill E. Stopfer, Dana R. Lilli, Nancy Hamel, Marc D. Tischkowitz, Álvaro N.A. Monteiro, Troy E. Messick, Jacquelyn Powers, Alexandria Yonker et al. · 2012 · Cancer Discovery
40. Milk Production and Fertility in Cattle
    Donagh Pearse Berry, N.C. Friggens, M.C. Lucy, John R. Roche · 2015 · Annual Review of Animal Biosciences
41. Realizing the Promise of Genomics in Biomedical Research
    Alan E. Guttmacher, Francis S. Collins · 2005 · JAMA
42. Results of Annual Screening in Phase I of the United Kingdom Familial Ovarian Cancer Screening Study Highlight the Need for Strict Adherence to Screening Schedule
    Adam N. Rosenthal, Lindsay Sarah Macduff Fraser, Ranjit Manchanda, Philip David Badman, Susan Philpott, Jessica T. Mozersky, Richard J. Hadwin, Fay Helen Cafferty, Eromosele Oseiwe Benjamin, Naveena Singh et al. · 2012 · Journal of Clinical Oncology
43. The association of BRCA1 and BRCA2 mutations with prostate cancer risk, frequency, and mortality: A meta‐analysis
    Mok Oh, Nasser Alkhushaym, Saad Fallatah, Abdulhamid A. Althagafi, Rana Aljadeed, Yazed Saleh Alsowaida, Joanne Jeter, Jennifer R Martin, Hani M. Babiker, Ali McBride et al. · 2019 · The Prostate
44. Risk Assessment, Genetic Counseling, and Genetic Testing forBRCA-Related Cancer in Women
    Heidi D Nelson, Miranda Pappas, Amy G. Cantor, Elizabeth M Haney, Rebecca S. Holmes · 2019 · JAMA
45. Molecular Diagnostics in Clinical Oncology
    Анна Петровна Соколенко, Евгений Наумович Имянитов · 2018 · Frontiers in Molecular Biosciences
46. Large scale multifactorial likelihood quantitative analysis of BRCA1 and BRCA2 variants: An ENIGMA resource to support clinical variant classification
    M. Parsons, Emma Tudini, Hong-Yan Li, E. Hahnen, B. Wappenschmidt, L. Feliubadaló, C. Aalfs, S. Agata, K. Aittomäki, E. Alducci et al. · 2019 · Human Mutation
47. Reproductive and Hormonal Factors, and Ovarian Cancer Risk for BRCA1 and BRCA2 Mutation Carriers: Results from the International BRCA1/2 Carrier Cohort Study
    Antonis C. Antoniou, Matti A. Rookus, Nadine Andrieu, Richard M. Brohet, Jenny C. Chang-Claude, Susan Peock, Margaret Cook, D. Gareth Evans, Rosalind A. Eeles, EMBRACE et al. · 2009 · Cancer Epidemiology Biomarkers & Prevention
48. BRCA1 expression and improved survival in ovarian cancer patients treated with intraperitoneal cisplatin and paclitaxel: a Gynecologic Oncology Group Study
    Jamie Lee Lesnock, Kathleen M. Darcy, Chunqiao Tian, Julie A. DeLoia, Melissa M. Thrall, Chris M. Zahn, Deborah Kay Armstrong, Michael J. Birrer, Thomas C. Krivak · 2013 · British Journal of Cancer
49. Breast and ovarian cancer risks to carriers of the BRCA1 5382insC and 185delAG and BRCA2 6174delT mutations: a combined analysis of 22 population based studies
    Antonis C. Antoniou, Paul D.P. Pharoah, Steven Alexander Narod, Harvey A. Risch, Jorunn Erla Eyfjord, John Llewelyn Hopper, Hakan Lars Olsson, Oskar T. Johannsson, Åke Borg, Barbara Pasini et al. · 2005 · Journal of Medical Genetics
50. Common and rare forms of diabetes mellitus: towards a continuum of diabetes subtypes
    Jason A. Flannick, Stefan Johansson, Pål R. Njølstad · 2016 · Nature Reviews Endocrinology
51. Follow-up of carriers of BRCA1 and BRCA2 variants of unknown significance: Variant reclassification and surgical decisions
    Mitzi L. Murray, Felecia E. Cerrato, Robin L. Bennett, Gail Pairitz Jarvik · 2011 · Genetics in Medicine
52. BRCA1 and BRCA2 Gene Mutations and Colorectal Cancer Risk: Systematic Review and Meta-analysis
    Mok Oh, Ali McBride, Seongseok Yun, Sandipan Bhattacharjee, Marion Kimball Slack, Jennifer R Martin, Joanne Jeter, Ivo L Abraham · 2018 · JNCI Journal of the National Cancer Institute
53. Incidence of colorectal cancer in BRCA1 and BRCA2 mutation carriers: results from a follow-up study
    the Hereditary Breast Cancer Study Group, Catherine M. Phelan, Javaid Iqbal, Henry T. Lynch, Jan Lubiński, Jacek Gronwald, Pål Møller, Parviz Ghadirian, William David Foulkes, Susan Randall Armel et al. · 2013 · British Journal of Cancer
54. The risk of endometrial cancer in women with BRCA1 and BRCA2 mutations. A prospective study
    Mario E. Beiner, Amy Finch, Barry P. Rosen, Jan Lubiński, Pål Møller, Parviz Ghadirian, Henry T. Lynch, Eitan Friedman, Ping Sun, Steven Alexander Narod · 2006 · Gynecologic Oncology
55. Biology of Epithelial Ovarian Cancer: Implications for Screening Women at High Genetic Risk
    Russell J. Hogg, Michael Leonard Friedlander · 2004 · Journal of Clinical Oncology
56. Polygenic risk scores and breast and epithelial ovarian cancer risks for carriers of BRCA1 and BRCA2 pathogenic variants
    Daniel R. Barnes, Matti A. Rookus, Lesley McGuffog, Goska Leslie, Thea M. Mooij, Joe Dennis, Nasim Mavaddat, Julian Adlard, Munaza Ahmed, Kristiina Aittomäki et al. · 2020 · Genetics in Medicine
57. The Breast Cancer Susceptibility Mutation PALB2 1592delT Is Associated with an Aggressive Tumor Phenotype
    Tuomas Heikkinen, Hanni Kärkkäinen, Kirsimari Aaltonen, Roger Laughlin Milne, Päivi Heikkilä, Kristiina Aittomäki, CARL P. BLOMQVIST, Heli A. Nevanlinna · 2009 · Clinical Cancer Research
58. Genetic susceptibility for breast cancer: How many more genes to be found?
    R.A. Oldenburg, Hanne E.J. Meijers-Heijboer, Cees J. Cornelisse, Peter Devilee · 2007 · Critical Reviews in Oncology/Hematology
59. Views of BRCA gene mutation carriers on preimplantation genetic diagnosis as a reproductive option for hereditary breast and ovarian cancer
    Usha Menon, Joyce Catherine Harper, Aarti Sharma, Lindsay Sarah Macduff Fraser, Matthew Burnell, Karim Elmasry, Charles H. Rodeck, Ian J. Jacobs · 2007 · Human Reproduction
60. Outcome of risk-reducing salpingo-oophorectomy in BRCA carriers and women of unknown mutation status
    Ranjit Manchanda, Ahmed R. Abdelraheim, Michelle Johnson, Adam N. Rosenthal, Eromosele Oseiwe Benjamin, Carol Brunell, Matthew Burnell, Lucy E. Side, Sue Gessler, Ertan Sarıdoğan et al. · 2011 · BJOG An International Journal of Obstetrics & Gynaecology
61. Current Treatment Landscape for Early Triple-Negative Breast Cancer (TNBC)
    Jieun Lee · 2023 · Journal of Clinical Medicine
62. Prognosis of BRCA-associated breast cancer: a summary of evidence
    Bordeleau, L., Panchal, S., Goodwin, P. · 2010 · Breast Cancer Research and Treatment
63. BRCA mutation in ovarian cancer: testing, implications and treatment considerations
    Robert T. Neff, Leigha A. Senter, Ritu Salani · 2017 · Therapeutic Advances in Medical Oncology
64. Clinical Effects of Early or Surgical Menopause
    Sheryl A. Kingsberg, Lisa C. Larkin, JAMES H. LIU · 2020 · Obstetrics and Gynecology
65. Oral Contraceptive Use and Risk of Early-Onset Breast Cancer in Carriers and Noncarriers of BRCA1 and BRCA2 Mutations
    Roger Laughlin Milne, Julia A. Knight, Esther M. John, Gillian S. Dite, Ronald Balbuena, Argyrios Ziogas, Irene Louise Andrulis, Dee W. West, Frederick P. Li, Melissa C. Southey et al. · 2005 · Cancer Epidemiology Biomarkers & Prevention
66. Prophylactic Oophorectomy Reduces Breast Cancer Penetrance During Prospective, Long-Term Follow-Up of BRCA1 Mutation Carriers
    Joan L. Kramer, Isela A. Velazquez, Bingshu E. Chen, Philip S. Rosenberg, Jeffery P. Struewing, Mark H. Greene · 2005 · Journal of Clinical Oncology
67. Clinical significance of large rearrangements in BRCA1 and BRCA2
    Thaddeus Judkins, Eric Rosenthal, Christopher Arnell, Lynn Anne Burbidge, Wade Geary, Toby Barrus, Jeremy Schoenberger, Jeffrey T. Trost, RICHARD J. WENSTRUP, Benjamin B. Roa · 2012 · Cancer
68. Mammographic Density and Breast Cancer Risk in BRCA1 and BRCA2 Mutation Carriers
    Gillian Mitchell, Antonis C. Antoniou, Ruth M. L. Warren, Susan Peock, Judith D. Brown, Russell Davies, Jenny Mattison, Margaret Cook, Iqbal Warsi, D. Gareth Evans et al. · 2006 · Cancer Research
69. Prevalence of deleterious germline variants in risk genes including BRCA1/2 in consecutive ovarian cancer patients (AGO-TR-1)
    Philipp Harter, Jan Hauke, Florian Heitz, Alexander Reuß, Stefan Kommoss, Frederik Marmé, André Heimbach, Katharina Prieske, Lisa Richters, Alexander Burges et al. · 2017 · PLoS ONE
70. Cancer genetics, precision prevention and a call to action
    Clare Turnbull, Amit Sud, Richard S. Houlston · 2018 · Nature Genetics
71. European polygenic risk score for prediction of breast cancer shows similar performance in Asian women
    Weang-Kee Ho, Min Tan, Nasim Mavaddat, Mei-Chee Tai, Shivaani Mariapun, Jingmei Li, Peh Joo Ho, Joe Dennis, Jonathan P. Tyrer, Manjeet K. Bolla et al. · 2020 · Nature Communications
72. Risk-Reducing Salpingo-Oophorectomy in Patients With Germline Mutations in BRCA1 or BRCA2
    Noah D. Kauff, Richard R. Barakat · 2007 · Journal of Clinical Oncology
73. NSGC Practice Guideline: Risk Assessment and Genetic Counseling for Hereditary Breast and Ovarian Cancer
    Janice L. Berliner, Angela Musial Fay, Shelly Ann Cummings, Brittany Boldt Burnett, Todd Tillmanns · 2012 · Journal of Genetic Counseling
74. Public health implications from COGS and potential for risk stratification and screening
    Hilary Burton, Susmita Chowdhury, Tom Dent, Alison Hall, Nora Pashayan, Paul D.P. Pharoah · 2013 · Nature Genetics
75. Identifying breast cancer susceptibility genes – a review of the genetic background in familial breast cancer
    Camilla Wendt, Sara Margolin · 2019 · Acta Oncologica
76. The CRM1 nuclear export protein in normal development and disease.
    Kevin T. Nguyen, Michael P. Holloway, Rachel A. Altura · 2012 · Europe PMC (PubMed Central)
77. Incidental Carcinomas in Prophylactic Specimens in BRCA1 and BRCA2 Germ-line Mutation Carriers, With Emphasis on Fallopian Tube Lesions
    Maria Luisa Carcangiu, Bernard Peissel, Barbara Pasini, Gianbattista Spatti, Paolo Radice, Siranoush Manoukian · 2006 · The American Journal of Surgical Pathology
78. Effect of Oophorectomy on Survival After Breast Cancer inBRCA1andBRCA2Mutation Carriers
    Kelly A. Metcalfe, Henry T. Lynch, William David Foulkes, Nadine Tung, Charmaine Kim‐Sing, Olufunmilayo Ibironke Olopade, Andrea F. Eisen, Barry P. Rosen, Carrie Snyder, Shelley Gershman et al. · 2015 · JAMA Oncology
79. Role of Artificial Intelligence in Radiogenomics for Cancers in the Era of Precision Medicine
    Sanjay Saxena, Biswajit Jena, Neha Gupta, Suchismita Das, Deepaneeta Sarmah, Pallab Bhattacharya, Tanmay Nath, Sudip Paul, Mostafa M. Fouda, Manudeep K. Kalra et al. · 2022 · Cancers
80. Population-Based Study of Changing Breast Cancer Risk in Icelandic BRCA2 Mutation Carriers, 1920–2000
    Laufey Tryggvadóttír, Helgi Sigvaldason, Guðríður H. Ólafsdóttir, Jon Gunnlaugur Jonasson, Þorvaldur Jónsson, Hrafn Tulinius, Jorunn Erla Eyfjord · 2006 · JNCI Journal of the National Cancer Institute
81. Nipple-Sparing Mastectomy in BRCA1/2 Mutation Carriers: An Interim Analysis and Review of the Literature
    Katharine A. Yao, Erik Liederbach, Rong Tang, Lan Lei, Tomasz Czechura, Mark Sisco, Michael A. Howard, Peter J. Hulick, David J. Winchester, Suzanne B. Coopey et al. · 2014 · Annals of Surgical Oncology
82. Effectiveness of Screening With Annual Magnetic Resonance Imaging and Mammography: Results of the Initial Screen From the Ontario High Risk Breast Screening Program
    Anna Maria Chiarelli, Maegan V. Prummel, Derek Muradali, Vicky Majpruz, Meaghan Horgan, June C. Carroll, Andrea F. Eisen, Wendy S. Meschino, Rene S. Shumak, Ellen Warner et al. · 2014 · Journal of Clinical Oncology
83. Breast cancer: Epidemiology, risk factors and screening
    Hangcheng Xu, Binghe Xu · 2023 · Chinese Journal of Cancer Research
84. The risk of contralateral breast cancer in patients from BRCA1/2 negative high risk families as compared to patients from BRCA1 or BRCA2 positive families: a retrospective cohort study
    Kerstin Rhiem, Christoph Engel, Monika Graeser, Silke Zachariae, Karin Kast, Marion B. Kiechle, Nina Caroline Ditsch, Wolfgang J. Janni, Christoph Mundhenke, Michael Golatta et al. · 2012 · Breast Cancer Research
85. Hereditary diffuse gastric cancer: association with lobular breast cancer
    Kasmintan A. Schrader, Serena Masciari, Niki Boyd, Sara J. Wiyrick, Pardeep Kaurah, Janine Senz, Wylie Burke, Henry T. Lynch, Judy Ellen Garber, David D. Huntsman · 2007 · Familial Cancer
86. Epithelial Ovarian Cancer: Disease Etiology, Treatment, Detection, and Investigational Gene, Metabolite, and Protein Biomarkers
    Taufika Islam Williams, Kristina L. Toups, Diana A. Saggese, Kimberly R. Kalli, William A. Cliby, David C. Muddiman · 2007 · Journal of Proteome Research
87. DNA Glycosylases Involved in Base Excision Repair May Be Associated with Cancer Risk in BRCA1 and BRCA2 Mutation Carriers
    Ana Osório, Roger Laughlin Milne, Karoline B. Kuchenbaecker, Tereza Vaclová, Guillermo Pita, Rosario Alonso, Paolo Peterlongo, Ignacio Blanco, Miguel de la Hoya, Mercedes Duran et al. · 2014 · PLoS Genetics
88. Second Primary Breast Cancer Occurrence According to Hormone Receptor Status
    Allison W. Kurian, Leslie Ain McClure, Esther M. John, Pamela L. Horn‐Ross, James M. Ford, Christina A. Clarke · 2009 · JNCI Journal of the National Cancer Institute
89. BRCA1/BRCA2Pathogenic Variant Breast Cancer: Treatment and Prevention Strategies
    Anbok Lee, Byung-In Moon, Tae Hyun Kim · 2019 · Annals of Laboratory Medicine
90. Expanding the Criteria for BRCA Mutation Testing in Breast Cancer Survivors
    Janice S. Kwon, Angelica M. Gutierrez‐Barrera, Diana Young, Charlotte C. Sun, Molly S. Daniels, Karen H. Lu, Banu Arun · 2010 · Journal of Clinical Oncology
91. Utilization and Outcomes ofBRCAGenetic Testing and Counseling in a National Commercially Insured Population
    Joanne Armstrong, Michele Toscano, Nancy Kotchko, Sue J. Friedman, Marc D. Schwartz, Katherine S. Virgo, Kristian Francis Lynch, James E. Andrews, Claudia X. Aguado Loi, Joseph E. Bauer et al. · 2015 · JAMA Oncology
92. Validity of Models for Predicting BRCA1 and BRCA2 Mutations
    Giovanni Parmigiani, Sining Chen, Edwin S. Iversen, Tara M. Friebel, Dianne M. Finkelstein, Hoda Anton-Culver, Argyrios Ziogas, Barbara L. Weber, Andrea F. Eisen, Kathleen E. Malone et al. · 2007 · Annals of Internal Medicine
93. The counsellees' view of an unclassified variant in BRCA1/2: recall, interpretation, and impact on life
    Joël Vos, Wilma Otten, Christie J. van Asperen, Anna Jansen, Fred H. Menko, Aad Tibben · 2007 · Psycho-Oncology
94. Annual screening strategies in BRCA1 and BRCA2 gene mutation carriers
    Kathryn P. Lowry, Janie M. Lee, Chung Yin Kong, Pamela M. McMahon, Michael E. Gilmore, Jessica E. Cott Chubiz, Etta D. Pisano, Constantine A. Gatsonis, Paula D. Ryan, Elissa M. Ozanne et al. · 2011 · Cancer
95. Breastfeeding reduces the risk of breast cancer: A call for action in high‐income countries with low rates of breastfeeding
    Britta Stordal · 2022 · Cancer Medicine
96. Changes in body weight and the risk of breast cancer in BRCA1 and BRCA2mutation carriers
    Joanne Kotsopoulos, Olufunmilayo Ibironke Olopade, Parviz Ghadirian, Jan Lubiński, Henry T. Lynch, Claudine J. Isaacs, Barbara Weber, Charmaine Kim‐Sing, Peter Ainsworth, William David Foulkes et al. · 2005 · Breast Cancer Research
97. Identification et prise en charge des prédispositions héréditaires aux cancers du sein et de l'ovaire (mise à jour 2004)
    François Eisinger, Brigitte Bressac–de Paillerets, Damienne Castaigne, Paul Henri Cottu, Jacques Lansac, Jean‐Pierre Lefranc, A. Lesur, Catherine Noguès, Janine Pierret, Séverine Puy‐Pernias et al. · 2006 · Pathologie Biologie
98. BRCA1 R1699Q variant displaying ambiguous functional abrogation confers intermediate breast and ovarian cancer risk
    Amanda B. Spurdle, Phillip J Whiley, Bryony A. Thompson, Bing Feng, Sue C. Healey, Melissa A. Brown, Christopher A. Pettigrew, kConFab, Christie J. van Asperen, Margreet G.E.M. Ausems et al. · 2012 · Journal of Medical Genetics
99. Prevalence of BRCA1 Mutation Carriers among U.S. Non-Hispanic Whites
    Alice S. Whittemore, Gail D. Gong, Esther M. John, Valerie M. McGuire, Frederick P. Li, Kimberly Laskie Ostrow, Richard A. DiCioccio, Anna Felberg, Dee W. West · 2004 · Cancer Epidemiology Biomarkers & Prevention
100. Refined histopathological predictors of BRCA1 and BRCA2mutation status: a large-scale analysis of breast cancer characteristics from the BCAC, CIMBA, and ENIGMA consortia
     Amanda B. Spurdle, Fergus J. Couch, Michael T. Parsons, Lesley McGuffog, Daniel Barrowdale, Manjeet K. Bolla, Qin Wang, Sue C. Healey, Rita Katharina Schmutzler, Barbara Wappenschmidt et al. · 2014 · Breast Cancer Research